Biotech entity
The clearest coverage concentration is clinical-trial: 4 of 5 stories, with the rest divided among 1 other category. Negative sentiment reaches 60% here, compared with 25% across the 128-story beat baseline for the same window. Ituri province is the most frequent co-covered peer, appearing in 3 of the 5 tracked stories.
Last mentioned: Jul 13, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 40 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
The clearest coverage concentration is clinical-trial: 4 of 5 stories, with the rest divided among 1 other category. Negative sentiment reaches 60% here, compared with 25% across the 128-story beat baseline for the same window. Ituri province is the most frequent co-covered peer, appearing in 3 of the 5 tracked stories. They are less corroborated than the beat average, carrying 3.2 original sources each against 4.4 for the same window. Across a 23-day span, the pace is roughly 1.5 stories per week. The 7 average consequence score is above the beat benchmark of 6.3 in the same window. We currently track 5 Biotech stories that mention Bundibugyo ebolavirus, published between July 13, 2026 and August 4, 2026.
Computed from the 5 stories linked to this entity, with beat comparisons drawn from all 128 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Bundibugyo ebolavirus. Shared-story counts are live from our verified record — not editorial picks.
Leadership Visits and Latest Data Released
Africa CDC Director-General Jean Kaseya visited Bunia, WHO Director-General Tedros arrived in Kinshasa; government update reported 3,802 cases and 1,707 deaths.
Healthcare Workers Issue Ultimatum
In Mongbwalu, healthcare workers threatened to escalate action within 24 hours if unpaid wages were not resolved.
WHO sounds alarm
WHO reports that 80% of new cases are from unknown chains of transmission; striking workers agree to return if paid within 72 hours.
Ethics Approval Received
NanoViricides announces National Ethics Committee approval for Phase II trial of NV-387 oral gummies for Ebola.
Health worker strike
Dozens of healthcare workers at an Ebola treatment centre in Bunia go on strike over unpaid salaries and bonuses.
Staff strike at Rwampara General Hospital
Dozens of workers at the epicenter treatment center strike over two months of unpaid salaries, shutting the facility and blocking roads.
Outbreak Worsens
DRC public health institute reports 1,926 confirmed Ebola cases and 702 deaths, with spread to Haut-Uele and Tshopo provinces.
Virus spreads to two more provinces
Health Minister Kamba announces the outbreak has reached two additional provinces beyond Ituri, further complicating containment.
Experimental treatment study begins
A clinical study of two candidate Ebola treatments launches at a different treatment center in Ituri province, not the one that would later strike.
Uganda Declared Ebola‑Free
Neighboring Uganda discharged its last Ebola patient, ending its own transmission chain linked to the Congo outbreak.
Official outbreak declaration
Congolese authorities declare a Bundibugyo Ebola outbreak after weeks of undetected transmission due to initial misdiagnosis.
Outbreak Declared
Eastern Congo Ebola outbreak officially declared, later linked to Bundibugyo virus.
Outbreak identified
Congo detects an outbreak of the rare Bundibugyo Ebola virus in the eastern part of the country.
Congo’s Bundibugyo Ebola outbreak has surged to 3,802 cases and 1,707 deaths, highlighting an urgent need for vaccines and treatments. With no approved products available, two post‑exposure prophylaxis trials in Ituri and two vaccine trials in the UK and Canada are now underway, while nearly 80% of new cases elude contact tracing.
Source: wfmj.com · orlandosentinel.com
Biotech's race to develop therapies for the Bundibugyo Ebola strain faces a new hurdle as a strike at Congo's outbreak epicenter disrupts critical clinical operations. The study of two candidate treatments, launched in early July, could be jeopardized by collapsed workforce morale at nearby facilities.
Source: mcall.com
The fastest-growing Ebola outbreak in history is driven by the Bundibugyo virus, which lacks any approved vaccine or therapy. With over 2,100 cases and 864 deaths, biopharma companies face a pressing unmet need and a potential market for rapid filovirus countermeasure development.
Source: wral.com · breitbart.com
With 80% of new Ebola cases from unknown chains and the rare Bundibugyo strain lacking any approved vaccine or treatment, this outbreak exposes a critical gap in the biopharma pipeline and may catalyse urgent R&D investment.
NanoViricides (NYSE American: NNVC) has crossed a major regulatory hurdle with DRC ethics committee approval for its Phase II trial of NV-387 oral gummies for Ebola. The company leverages its nanoviricide platform against an underserved Bundibugyo strain, positioning itself uniquely in the infectious disease space with a potential first-in-class oral antiviral.
Source: newjerseytelegraph.com · hawaiitelegraph.com
Bundibugyo ebolavirus is linked from 5 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
